Omontys a treatment for anemia in patients with chronic kidney disease on dialysis. Anemia is a decrease of red blood cells in the body. The medication promotes red blood cell development.
Reports from U.S.dialysis centers show nineteen cases of anaphylaxis and three deaths. Where patients have whole-body allergic reactions. 2% of patients required medical intervention.
The fatal reactions occurred within 30 minutes of the first intravenous dose. There are no reports of reactions after other dosing or in patients finished with their treatments of dialysis have not been. The cause of these fatal reactions is unknown. Affymax is analyzing data, according to Bloomberg, from patients who have experienced reactions to the medication.
There has been a recall for Omontys! No new patients should take this drug!
If you or someone you love had a serious reaction to an Omontys injection, contact The Law Offices of L. Clayton Burgess for a free personal injury consultation.
